Diabetic Eye Disease Viewpoint Ang2 inhibition for retinal disease Astigmatism Correction Carl Zeiss Case Studies Extending dosing of anti-VEGF Retina Disorders Retina Drug Delivery Retina in 2020 Updates From Angiogenesis 2021 Updates from ASRS 2021

Diabetic Eye Disease Viewpoint Ang2 inhibition for retinal disease Astigmatism Correction Carl Zeiss Case Studies Extending dosing of anti-VEGF Retina Disorders Retina Drug Delivery Retina in 2020 Updates From Angiogenesis 2021 Updates from ASRS 2021

View More Cataract & Refractive Cornea Gene Therapy Glaucoma Inflammation & Infection Paediatrics Retina

Cataract & Refractive Cornea Gene Therapy Glaucoma Inflammation & Infection Paediatrics Retina

Medical World News

Updates From Angiogenesis 2021

Eyeviews Medical World News Podcasts Rapid Readouts Updates From Angiogenesis 2021 Viewpoints

Digital Edition

Supplements And Featured Publications

Digital Edition Supplements And Featured Publications

Conference Coverage

Conference Listing

Conference Coverage Conference Listing

Sponsored Resources

Zeiss Case Studies

Sponsored Resources Zeiss Case Studies

Print Subscription

eNewsletter Print Subscription

Advertise
Editorial Info
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2021 MJH Life Sciences and Opthalmology Times Europe. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

Diabetic Eye Disease Viewpoint
Ang2 inhibition for retinal disease
Astigmatism Correction
Carl Zeiss Case Studies
Extending dosing of anti-VEGF
Retina Disorders
Retina Drug Delivery
Retina in 2020
Updates From Angiogenesis 2021
Updates from ASRS 2021

ClinicalSee All >

Cataract & Refractive
Cornea
Gene Therapy
Glaucoma
Inflammation & Infection
Paediatrics
Retina

Advertise
Editorial Info
Contact Us
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2021 MJH Life Sciences^™ and Opthalmology Times Europe. All rights reserved.

AMO completes IntraLase acquisition

April 30, 2007

Advanced Medical Optics (AMO) has completed its acquisition of IntraLase Corp.

Related Content:

Newer CPC laser technologies are improving glaucoma outcomes

Newer CPC laser technologies are improving glaucoma outcomes

Identifying individuals at risk of glaucoma via genetics studies

Identifying individuals at risk of glaucoma via genetics studies

Current approaches to treatment of uveitis with autoimmune disease

Current approaches to treatment of uveitis with autoimmune disease